Botanix Pharmaceuticals Ltd has released a press release.
FDA Clears Development Path for BTX 1204
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Botanix Pharmaceuticals
- Investigators Meeting Completed for BTX 1503 Phase 2 Trial
- Botanix Joins with UQ to Accelerate Development of BTX 1801
- Botanix update on development pipeline products
- First Patients Recruited into BTX 1503 Phase 2 Acne Trial
- BOT Welcomes First FDA Approval for Cannabidiol Product
Later from Botanix Pharmaceuticals
- Botanix BTX 1503 Clinical Trial Update
- Ethics Approval for BTX 1308 Psoriasis Patient Study Secured
- First Patient Treated in BTX 1308 Psoriasis Patient Study
- Botanix receives A$4.6m R&D Tax Incentive refund
- Ethics Approval for Phase 2 Atopic Dermatitis Study Received
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals